XORTX Therapeutics Inc. Common Stock (XRTX)

Price$2.22

Value ScoreB

Momentum ScoreD

Favorite Metrics

Price vs S&P 500 (26W)-58.48%

Price vs S&P 500 (4W)-21.81%

VGM Score53.19

Market Capitalization$5.48M

All Metrics

Book Value / Share (Quarterly)$1.50

P/TBV (Annual)2.11x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-20.19%

Cash Flow / Share (Quarterly)$-2.03

Price vs S&P 500 (YTD)-28.44%

Gross Margin (TTM)21.01%

Net Profit Margin (TTM)-2.60%

EPS (TTM)$-2.25

10-Day Avg Trading Volume0.00M

EPS Excl Extra (TTM)$-2.25

EPS (Annual)$-2.81

ROI (Annual)-125.19%

Gross Margin (Annual)21.01%

Cash / Share (Quarterly)$0.62

ROA (Last FY)-98.99%

EBITD / Share (TTM)$-1.86

ROE (5Y Avg)-78.68%

Operating Margin (TTM)-0.27%

Cash Flow / Share (Annual)$-2.03

P/B Ratio1.90x

P/B Ratio (Quarterly)1.92x

Net Income / Employee (Annual)$-885,400

Net Interest Coverage (TTM)-131.30x

ROA (TTM)-90.54%

EPS Incl Extra (Annual)$-2.81

Current Ratio (Annual)2.11x

Quick Ratio (Quarterly)2.07x

3-Month Avg Trading Volume0.00M

52-Week Price Return-67.95%

Revenue / Employee (TTM)$271,440,000

Tangible BV / Share (Quarterly)$1.36

P/S Ratio (Annual)0.00x

Asset Turnover (Annual)2.01x

52-Week High$9.85

EPS Excl Extra (Annual)$-2.81

CapEx CAGR (5Y)38.81%

26-Week Price Return-42.55%

Quick Ratio (Annual)2.07x

13-Week Price Return-21.98%

Total Debt / Equity (Annual)0.02x

Current Ratio (Quarterly)2.11x

Enterprise Value$3.14M

Asset Turnover (TTM)1.88x

Revenue / Employee (Annual)$271,440,000

Inventory Turnover (Annual)4.23x

Pretax Margin (Annual)-0.24%

Cash / Share (Annual)$0.62

3-Month Return Std Dev161.61%

Net Income / Employee (TTM)$-885,400

ROE (Last FY)-127.43%

Net Interest Coverage (Annual)-0.77x

EPS Basic Excl Extra (Annual)$-2.81

P/FCF (TTM)7.53x

Total Debt / Equity (Quarterly)0.02x

EPS Incl Extra (TTM)$-2.25

Receivables Turnover (Annual)15.35x

ROI (TTM)-117.76%

P/S Ratio (TTM)0.00x

Revenue / Share (Annual)$29.65

Tangible BV / Share (Annual)$1.36

Price vs S&P 500 (52W)-67.56%

Year-to-Date Return-17.92%

5-Day Price Return1.61%

EPS Normalized (Annual)$-2.81

ROA (5Y Avg)-57.85%

Net Profit Margin (Annual)-2.60%

Month-to-Date Return-16.18%

Cash Flow / Share (TTM)$-4.98

EBITD / Share (Annual)$-3.32

Operating Margin (Annual)-0.27%

LT Debt / Equity (Annual)0.13x

ROI (5Y Avg)-77.74%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-2.25

P/TBV (Quarterly)2.11x

P/B Ratio (Annual)1.92x

Pretax Margin (TTM)-0.24%

Book Value / Share (Annual)$1.50

Price vs S&P 500 (13W)-31.72%

Beta0.03x

P/FCF (Annual)50.44x

Revenue / Share (TTM)$29.55

ROE (TTM)-120.33%

52-Week Low$2.42

vGradeB

mGradeD

vgmGradeC

Show chart for

Analyst Recommendations

Dec 2023

Jan 2024

Feb 2024

Mar 2024

4.00

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
XRTXXORTX Therapeutics Inc. Common Stock	B	—	D	$2.22
LLYEli Lilly & Co.	D	B	B	$1082.20
JNJJohnson & Johnson	C	C	C	$223.51
ABBVABBVIE INC.	D	C	C	$212.93
MRKMerck & Co., Inc.	C	C	C	$115.17
NVSNovartis AG	C	C	C	$145.68
AZNAstraZeneca PLC	D	B	C	$179.71
NVONovo-Nordisk A/S	B	B	C	$44.07
ABTAbbott Laboratories	C	C	D	$87.78
PFEPfizer Inc.	B	C	C	$25.63
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$34.64

About

XORTX Therapeutics is a clinical-stage biotechnology company developing therapies for progressive kidney disease by targeting purine and uric acid metabolism. The company is advancing three therapeutic candidates for rare kidney disease indications including ADPKD and Type 2 Diabetic Nephropathy, as well as acute kidney injury associated with respiratory infections. The company aims to slow or reverse chronic kidney disease progression and explore additional indications leveraging its intellectual property.